Cencora
Cencora, formerly known as the Clinical Research Division of AmerisourceBergen, is a prominent player in the global pharmaceutical services industry. Headquartered in the United States, Cencora operates extensively across North America, Europe, and Asia, providing comprehensive solutions that span clinical trial management, supply chain logistics, and commercialisation services. Founded in 2022, the company has quickly established itself as a leader in the sector, leveraging its extensive expertise to support biopharmaceutical companies in bringing innovative therapies to market. Cencora's core offerings include tailored clinical trial services and advanced supply chain solutions, distinguished by their commitment to quality and efficiency. With a focus on enhancing patient access to critical medications, Cencora has achieved notable milestones, positioning itself as a trusted partner in the healthcare landscape. Its dedication to innovation and excellence continues to drive its success in an ever-evolving market.
DitchCarbon Score
How does Cencora's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Wholesale Trade industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cencora's score of 47 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cencora's reported carbon emissions
In 2023, Cencora reported total greenhouse gas emissions of approximately 25,878,873,000 kg CO2e, with emissions distributed across various scopes: 108,712,000 kg CO2e from Scope 1, 87,492,000 kg CO2e from Scope 2 (market-based), and 25,878,873,000 kg CO2e from Scope 3. This reflects a commitment to transparency in their carbon footprint, particularly in the healthcare sector. Cencora has set ambitious targets to reduce its carbon emissions, committing to a 54.6% reduction in absolute Scope 1 and 2 greenhouse gas emissions by FY2032, using FY2019 as the baseline year. Additionally, the company aims for 82% of its suppliers, based on spend, to establish science-based targets by FY2027. This commitment aligns with industry standards for climate action, demonstrating Cencora's dedication to sustainability and responsible environmental stewardship. Overall, Cencora's proactive approach to managing its carbon emissions and engaging suppliers in climate initiatives positions it as a leader in the healthcare sector's transition towards a more sustainable future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 98,742,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 100,593,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 19,881,916,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cencora is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
